Vitiligo
☆ Yn 'e 2022 Stiftung Warentest-resultaten út Dútslân wie de konsuminttefredenheid mei ModelDerm mar wat leger dan mei betelle telemedisynkonsultaasjes.
Vitiligo fan 'e fingers is dreger te behanneljen as oare gebieten. Njonken it kosmetysk ûnsichtber is vitiligo normaal en is net besmetlik. Yn dermatology is de meast effektive behanneling fototerapy of laserbehanneling (excimer) 2-3 kear yn 'e wike foar op syn minst 1 jier. As jo net faak nei it sikehûs kinne om finansjele redenen of om't jo it drok hawwe, kinne jo in fototerapymasine besykje dy't goedkard is foar thúsgebrûk.
Eyelid vitiligo
Vitiligo oan 'e hân
References
Vitiligo is in mienskiplike hûdsteuring dy't patches fan wite hûd feroarsake troch it ferlies fan melanozyten. Resint ûndersyk docht bliken dat it in autoimmune sykte is. Hoewol it faaks wurdt sjoen as in kosmetysk probleem, kin it geastlik wolwêzen en it deistich libben djip beynfloedzje. Yn 2011, saakkundigen klassifisearre in type neamd segmental vitiligo apart fan oaren.
Vitiligo is a common skin disorder that causes patches of white skin due to the loss of melanocytes. Recent research shows it's an autoimmune disease. While it's often seen as a cosmetic issue, it can deeply affect mental well-being and daily life. In 2011, experts classified a type called segmental vitiligo separately from others.
Vitiligo is a common skin disorder that causes patches of white skin due to the loss of melanocytes. Recent research shows it's an autoimmune disease. While it's often seen as a cosmetic issue, it can deeply affect mental well-being and daily life. In 2011, experts classified a type called segmental vitiligo separately from others.
Aktive vitiligo-pasjinten hawwe ferskate terapy-opsjes, lykas systemyske glukokortikoïden, fototerapy, en systemyske immunosuppressiva. Stabile vitiligo-pasjinten kinne reliëf fine fan topike kortikosteroïden, topyske kalsineurine-ynhibitoren, fototerapy en transplantaasjeprosedueres. Resinte foarútgong yn it begripen fan de ûnderlizzende prosessen fan vitiligo hawwe laat ta de ûntwikkeling fan rjochte terapyen. Op it stuit binne JAK-ynhibitoren de meast belofte, en biede goede tolerabiliteit en funksjonele resultaten, nettsjinsteande it risiko fan aktivearjen fan latinte ynfeksjes en systemyske side-effekten dy't mienskiplik binne mei oare immunosuppressive aginten. Oanhâldend ûndersyk hat as doel om wichtige cytokines te identifisearjen belutsen by de ûntwikkeling fan vitiligo (IFN-γ, CXCL10, CXCR3, HSP70i, IL-15, IL-17/23, TNF) . It blokkearjen fan dizze cytokines hat belofte toand yn diermodellen en guon pasjinten. Derneist binne ûndersiken nei miRNA-based therapeutics en adoptive Treg cell therapy oan 'e gong.
Current models of treatment for vitiligo are often nonspecific and general. Various therapy options are available for active vitiligo patients, including systemic glucocorticoids, phototherapy, and systemic immunosuppressants. While stable vitiligo patients may benefit from topical corticosteroids, topical calcineurin inhibitors, phototherapy, as well as transplantation procedures. Recently, a better understanding of the pathophysiological processes of vitiligo led to the advent of novel targeted therapies. To date, JAK inhibitors are the only category that has been proved to have a good tolerability profile and functional outcomes in vitiligo treatment, even though the risk of activation of latent infection and systemic side effects still existed, like other immunosuppressive agents. Research is in progress to investigate the important cytokines involved in the pathogenesis of vitiligo, including IFN-γ, CXCL10, CXCR3, HSP70i, IL-15, IL-17/23, and TNF, the blockade of which has undergone preliminary attempts in animal models and some patients. In addition, studies on miRNA-based therapeutics as well as adoptive Treg cell therapy are still primary, and more studies are necessary.
Current models of treatment for vitiligo are often nonspecific and general. Various therapy options are available for active vitiligo patients, including systemic glucocorticoids, phototherapy, and systemic immunosuppressants. While stable vitiligo patients may benefit from topical corticosteroids, topical calcineurin inhibitors, phototherapy, as well as transplantation procedures. Recently, a better understanding of the pathophysiological processes of vitiligo led to the advent of novel targeted therapies. To date, JAK inhibitors are the only category that has been proved to have a good tolerability profile and functional outcomes in vitiligo treatment, even though the risk of activation of latent infection and systemic side effects still existed, like other immunosuppressive agents. Research is in progress to investigate the important cytokines involved in the pathogenesis of vitiligo, including IFN-γ, CXCL10, CXCR3, HSP70i, IL-15, IL-17/23, and TNF, the blockade of which has undergone preliminary attempts in animal models and some patients. In addition, studies on miRNA-based therapeutics as well as adoptive Treg cell therapy are still primary, and more studies are necessary.
D'r is gjin bekende remedie foar vitiligo. Foar dyjingen mei ljochte hûd, sunscreen en make-up binne alles dat typysk wurdt oanrikkemandearre. Oare behannelingopsjes kinne steroide crèmes of fototerapy wêze.
○ Behanneling
#Phototherapy
#Excimer laser
#Tacrolimus ointment